RSS

Bioverativ

Sanofi has completed its acquisition of Bioverativ for $105 per share in cash. As a result, Bioverativ is now a fully owned subsidiary of Sanofi. more

News

A definitive acquisition agreement has been formed between Sanofi and biopharmaceutical company, Bioverativ, which will see Sanofi acquire all the outstanding shares of Bioverativ for an equity value of approximately $11.6 billion. more

News